Social Capital Suvretta Holdings Corp. III (DNAC): Price and Financial Metrics
DNAC Price/Volume Stats
| Current price | $9.28 | 52-week high | $10.55 |
| Prev. close | $10.00 | 52-week low | $8.03 |
| Day low | $9.24 | Volume | 338,800 |
| Day high | $10.55 | Avg. volume | 178,857 |
| 50-day MA | $9.83 | Dividend yield | N/A |
| 200-day MA | $9.86 | Market Cap | 237.94M |
DNAC Stock Price Chart Interactive Chart >
Social Capital Suvretta Holdings Corp. III (DNAC) Company Bio
Social Capital Suvretta Holdings Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. The company was incorporated in 2021 and is based in Henderson, Nevada.
Latest DNAC News From Around the Web
Below are the latest news stories about SOCIAL CAPITAL SUVRETTA HOLDINGS CORP III that investors may wish to consider to help them evaluate DNAC as an investment opportunity.
DNAC Stock: 11 Things to Know Ahead of the ProKidney SPAC MergerPalihapitiya's SPAC with ProKidney is expected to close during Q3 of this year. |
ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney DiseaseArticle published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), today announced the publication of the trial design of its Phase II clinical study of its novel Renal Autologous Cell Therapy (REACT®) in the American Journal of Nephrology. The paper, titled Novel Renal Autologous Cell |
7 Worst SPACs for Smart Investors to Skip in 2022SPACs may make a comeback in 2022. |
DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney MergerInvestors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. |
SOFI Stock: 11 Reasons Why Investors Are Banking On a SoFi Bank CharterSoFi Technologies (SOFI) stock is on the move Tuesday as investors discuss a bank charter for the company and what it could do to the stock. |
DNAC Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -6.07% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...